Compare Vistra Corp (VST) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vistra Corp vs GeneDx Holdings Corp — how do they compare? Vistra Corp trades at $159.15 (market cap $52.41B), while GeneDx Holdings Corp trades at $67.59 (market cap $2.02B). The key difference: Vistra Corp is far larger — about 25.9× GeneDx Holdings Corp's market cap, and Vistra Corp pays a 0.59% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vistra Corp for 32 Days and GeneDx Holdings Corp for 19 Days on average.
| VST | WGS | |
|---|---|---|
Market Cap | $52.41B | $2.02B |
Volume | 11,278,074 | 734,640 |
Sector | Utilities | Health |
52-Week High | $210.85 | $167.51 |
52-Week Low | $134.71 | $34.51 |
Typical Hold Time | 32 Days | 19 Days |
Enterprise Value | $74.34B | $2.05B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vistra Corp (VST) trades at $156.19, down 6.32% today, but maintains strong analyst support with 91% buy ratings and a $215.23 consensus target. The stock shows bullish technical signals with support at $152 and resistance at $164, while fundamentals reveal impressive 75.73% ROE and 11.55% net margin. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Vistra presents compelling growth potential as a key beneficiary of AI infrastructure expansion, with strong profitability metrics and institutional backing. However, investors face risks from volatile earnings performance (two recent EPS misses) and execution challenges in capital-intensive energy projects. The stock's current discount to analyst targets offers upside potential if the company can consistently deliver on its nuclear expansion and data center power contracts.
GeneDx (WGS) trades at $68.50, down 0.04% with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue of $114.4M beating expectations but net income margin remains negative at -23.4%. Recent developments include new product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus targets $81.00 (18% upside), fundamental challenges persist with negative profitability metrics and high valuation multiples. The stock faces execution risks amid competitive genomics landscape, but operational improvements and testing volume growth provide potential catalysts for recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
